Pediatric Use

BreathTek UBT is approved for use in children ages 3 to 17 years

Guidelines recommend against using antibody-based serology tests.1

It is recommended that one of following tests be used to determine whether H. pylori treatment was successful: (1) The 13C-UBT or (2) a 2 step monoclonal stool antigen test.

Confirming eradication is important because of:

  • Poor adherence with medications2
  • Reinfection due to intrafamilial transmission2
  • Increasing antibiotic resistance1
    • In children treated with standard H. pylori therapy, eradication rates have been decreasing over time, in part because of increased antibiotic resistance1
    • Data suggest high rates of H. pylori antibiotic resistance in some pediatric populations1,3
References
  • Jones NL, Koletzko S, Goodman K, et al. JPGN; H. pylori Working Groups of ESPGHAN, NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2017;64:991-1003.
  • Moya DA, Crissinger KD. Helicobacter pylori persistence in children: distinguishing inadequate treatment, resistant organisms, and reinfection. Curr Gastroenterol Rep. 2012;14(3):236-242.
  • Tolia V, Brown W, El-Baba M, Lin C-H. Helicobacter pylori culture and antimicrobial susceptibility from pediatric patients in Michigan. Pediatr Infect Dis J. 2000;19(2):1167-1171.